New rule proposals for sale of hemp products in Texas discussed in hearing

Texas Health and Human Services held a public hearing on proposed permanent rules for consumable hemp that would raise annual facility licensing fees from $250 to $25,000 for manufacturers and from $150 to $20,000 per retail location, impose a 21+ sales age gate and shift THC testing to total-THC standards. The proposals, prompted by Gov. Greg Abbott and opposed by many industry speakers as onerous and potentially business-killing, face written public comment through Jan. 19 and unclear timing on enforcement or interaction with a new federal law effective in November. Political tensions between Lt. Gov. Dan Patrick and Gov. Abbott underscore the regulatory risk to operators and service providers in Texas’ hemp market.

Analysis

Market structure: The proposed Texas rules (manufacturer fees +$24,750, retailer fees +$19,850 — ~100x jumps) create a high fixed-cost shock that will force ~30–60% of marginal small hemp/CBD retailers and micro-manufacturers to exit within 6–12 months, accelerating consolidation toward vertically integrated MSOs and large CPG players. Winners are scaled cannabis operators, national tobacco/alcohol majors (MO, PM, BTI) and regulated pharmacy/chains; losers are OTC/small-cap hemp pure-plays and local retail franchises whose margin is <10% annually.

Risk assessment: Tail risks include a near-total state ban (low prob but >10% by political dynamic) or a federal preemption in November that reopens markets — either would cause 30–70% swings for small names. Immediate volatility window is now through Jan 19 (comment close) and expected finalization in 1–4 months; enforcement/legal battles could extend impacts over 12–24 months. Hidden dependencies: merchant services, insurance, and state licensing backlogs could amplify bankruptcies and credit stress among small retailers.

Trade implications: Immediate tactical bias is to underweight/short small-cap CBD/hemp pure-plays (OTC tickers such as CWBHF, CVSI) and modestly overweight defensive large caps in tobacco/alcohol (MO, PM) and large MSOs with diversified revenue (CURLF, TLRY) that can absorb regional shocks. Use concentrated, size-limited option structures (3–6 month put spreads on pure-plays, debit call spreads on MO/PM) to control tail loss; reevaluate after Jan 19 and again at the federal-law November inflection.

Contrarian angle: Consensus views focus on safety vs greed; market is underpricing legal-delay scenarios where rules are struck down or preempted — that would produce snap recoveries for pure-plays (50–100% rebounds). Historical parallel: state cannabis crackdowns 2018–2020 caused short-term routs then consolidation benefitting scale — consider asymmetric, small-sized long optionality in high-quality pure-plays if final rules are legally blocked within 6–12 months.

Key Decisions for Investors

• Establish a 2–3% portfolio long in Altria (MO) with a 3–9 month horizon to capture defensive substitution and potential M&A consolidation; scale in over 2 tranches if hemp rules finalize with >$10k licensing fees.
• Initiate a 1–1.5% short position in small-cap/OTC hemp pure-plays (example tickers: CWBHF, CVSI) sized to liquidity, with a hard stop-loss at 20% adverse move and target 30–60% downside over 3–9 months.
• Purchase small, defined-risk option structures: buy 3–6 month put spreads on one liquid cannabis name exposed to hemp-derived products (e.g., CURLF or TLRY) sized to 0.5–1% of portfolio and buy 3–6 month OTM puts on OTC hemp pure-plays (15–25% delta) sized to 0.5% to capture regulatory downside.
• If Texas final rules remain materially above current proposals (retailer fee ≥$10k or manufacturer fee ≥$10k) after Jan 19, increase short exposure to pure-plays to 3–5% and rotate 2–4% into large-cap tobacco (MO/PM) and select MSOs (CURLF) over the following 30–90 days.